221
Participants
Start Date
April 20, 2015
Primary Completion Date
February 12, 2016
Study Completion Date
November 22, 2016
Apremilast
Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
Placebo
Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
Placebo-Apremilast
At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
Sadick Research Group, New York
Garden City Dermatology, Garden City
Dermatology Associates of Rochester PC, Rochester
Lawrence Green, MD, LLC, Rockville
Dermatology Consultants, Inc., Lynchburg
Dermatology and Laser Center of Charleston, Charleston
Dermatologic Surgery Specialists, P.C., Macon
USF Health Faculty Office Building-FOB, Tampa
Forward Clinical Trials Inc, Tampa
UAB at Birmingham - The Kirklin Clinic, Birmingham
Dermatology Specialists, PSC, Louisville
DermResearch, PLLC, Louisville
Shideler Clinical Research Center, Carmel
Henry Ford Hospital, Detroit
University of Utah School of Medicine, Salt Lake City
Las Vegas Skin and Cancer Clinics, Las Vegas
Dermatology Research Associates, Los Angeles
Blue Harbor Dermatology, Newport Beach
Tien Q. Nguyen MD Inc, Tustin
Center For Dermatology, Fremont
East Bay Rheumatology Medical, San Leandro
Center for Dermatology and Laser Surgery, Sacramento
UConn Health Center, Farmington
Dermatology Associates, Panama City
Psoriasis Treatment Center of Central New Jersey, East Windsor
University of Cincinnati, Cincinnati
Lead Sponsor
Amgen
INDUSTRY